Regeneron Sinks As Sales Of Key Eye Medication Tumble -- Market Talk

Dow Jones

Apr 30, 2025

1404 ET - Regeneron missed analysts' 1Q sales and earnings targets, driven by a 26% decline in sales of Eylea, the company's blockbuster vision-loss drug. Doctors are opting for lower-cost alternatives, in part because of problems Medicare patients are having getting copay assistance from nonprofit foundations funded by the pharmaceutical industry. Regeneron is trying to get other drugmakers to match its donations to the foundations so their programs are better funded, CEO Leonard Schleifer tells analysts. Regeneron sinks 7%; the stock has fallen 36% over the past 12 months as the company adjusts to generic competition for Eylea. (joseph.walker@wsj.com)

(END) Dow Jones Newswires

April 29, 2025 14:04 ET (18:04 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2531767519"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2531767519\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2531767519?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-30 02:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2531767519","market":"fut","top_or_hot":-1,"title":"Regeneron Sinks As Sales Of Key Eye Medication Tumble -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1404 ET - Regeneron missed analysts' 1Q sales and earnings targets, driven by a 26% decline in sales of Eylea, the company's blockbuster vision-loss drug. Doctors are opting for lower-cost alternatives, in part because of problems Medicare patients are having getting copay assistance from nonprofit foundations funded by the pharmaceutical industry. Regeneron is trying to get other drugmakers to match its donations to the foundations so their programs are better funded, CEO Leonard Schleifer tells analysts. Regeneron sinks 7%; the stock has fallen 36% over the past 12 months as the company adjusts to generic competition for Eylea. (joseph.walker@wsj.com) \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 29, 2025 14:04 ET (18:04 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Regeneron Sinks As Sales Of Key Eye Medication Tumble -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRegeneron Sinks As Sales Of Key Eye Medication Tumble -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-04-30 02:04</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1404 ET - Regeneron missed analysts' 1Q sales and earnings targets, driven by a 26% decline in sales of Eylea, the company's blockbuster vision-loss drug. Doctors are opting for lower-cost alternatives, in part because of problems Medicare patients are having getting copay assistance from nonprofit foundations funded by the pharmaceutical industry. Regeneron is trying to get other drugmakers to match its donations to the foundations so their programs are better funded, CEO Leonard Schleifer tells analysts. Regeneron sinks 7%; the stock has fallen 36% over the past 12 months as the company adjusts to generic competition for Eylea. (joseph.walker@wsj.com) \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 29, 2025 14:04 ET (18:04 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"REGN","symbol_name":"再生元制药公司","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2531767519","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2531767519","pubTimestamp":1745949840,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"1404 ET - Regeneron missed analysts' 1Q sales and earnings targets, driven by a 26% decline in sales of Eylea, the company's blockbuster vision-loss drug. Doctors are opting for lower-cost alternatives, in part because of problems Medicare patients are having getting copay assistance from nonprofit foundations funded by the pharmaceutical industry. Regeneron is trying to get other drugmakers to match its donations to the foundations so their programs are better funded, CEO Leonard Schleifer tells analysts. Regeneron sinks 7%; the stock has fallen 36% over the past 12 months as the company adjusts to generic competition for Eylea. ","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"REGN":"再生元制药公司"},"translate_title":"再生元(Regeneron)因主要眼科药物销量下滑而下滑——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"REGN":0.9},"content_text":"1404 ET - Regeneron missed analysts' 1Q sales and earnings targets, driven by a 26% decline in sales of Eylea, the company's blockbuster vision-loss drug. Doctors are opting for lower-cost alternatives, in part because of problems Medicare patients are having getting copay assistance from nonprofit foundations funded by the pharmaceutical industry. Regeneron is trying to get other drugmakers to match its donations to the foundations so their programs are better funded, CEO Leonard Schleifer tells analysts. Regeneron sinks 7%; the stock has fallen 36% over the past 12 months as the company adjusts to generic competition for Eylea. (joseph.walker@wsj.com) \n\n\n  (END) Dow Jones Newswires\n\n\n  April 29, 2025 14:04 ET (18:04 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}